131 related articles for article (PubMed ID: 34994612)
1. Metastatic Large-Cell Neuroendocrine Lung Carcinoma With ALK Fusion Oncogene With Partial Response to Alectinib.
Leblanc A; Owen S; Fiset PO; Gomez Corrador AL; Isenberg J; Bouganim N
JCO Precis Oncol; 2021 Nov; 5():802-807. PubMed ID: 34994612
[No Abstract] [Full Text] [Related]
2. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.
Hayashi N; Fujita A; Saikai T; Takabatake H; Sotoshiro M; Sekine K; Kawana A
Intern Med; 2018 Mar; 57(5):713-716. PubMed ID: 29151522
[TBL] [Abstract][Full Text] [Related]
3. [Alectinib and mixed large cell neuroendocrine carcinoma of the lung.].
Hegedűs F; Sükösd F; Tiszlavicz L; Furák J; Pálföldi R; Fejes Z; Zombori T
Orv Hetil; 2023 Apr; 164(14):548-554. PubMed ID: 37031440
[TBL] [Abstract][Full Text] [Related]
4. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
Popat S; Liu G; Lu S; Song G; Ma X; Yang JC
Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676
[TBL] [Abstract][Full Text] [Related]
5. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.
Shiihara J; Ohyanagi F; Amari H; Toda M; Tahara H; Yuzawa M; Maeda Y; Nomura M; Mizushina Y; Nagai Y; Ohta H; Yamaguchi Y
Thorac Cancer; 2021 Sep; 12(17):2420-2423. PubMed ID: 34324792
[TBL] [Abstract][Full Text] [Related]
6. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
7. A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib.
Lim CA; Banyi N; Tucker T; Ionescu DN; Melosky B
Curr Oncol; 2022 Feb; 29(2):848-852. PubMed ID: 35200571
[TBL] [Abstract][Full Text] [Related]
8. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
9. Next-Generation Sequencing Identified a Novel Crizotinib-Sensitive PLB1-ALK Rearrangement in Lung Large-Cell Neuroendocrine Carcinoma.
Wang S; Wu X; Zhao J; Chen H; Zhang Z; Wang M; Xu C; Wang Y; Wang L; He Z; Wang Q
Clin Lung Cancer; 2021 May; 22(3):e366-e370. PubMed ID: 32651063
[No Abstract] [Full Text] [Related]
10. A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib.
Omachi N; Shimizu S; Kawaguchi T; Tezuka K; Kanazu M; Tamiya A; Asami K; Okishio K; Kitaichi M; Atagi S
J Thorac Oncol; 2014 Jun; 9(6):e40-2. PubMed ID: 24828670
[No Abstract] [Full Text] [Related]
11. Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan.
Masuda N; Ohe Y; Gemma A; Kusumoto M; Yamada I; Ishii T; Yamamoto N
Cancer Sci; 2019 Apr; 110(4):1401-1407. PubMed ID: 30776174
[TBL] [Abstract][Full Text] [Related]
12. PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy.
Nagasaka M; Fisher A; Chowdhury T; Ge Y; Sukari A
Clin Lung Cancer; 2021 Jan; 22(1):e51-e53. PubMed ID: 32893122
[No Abstract] [Full Text] [Related]
13. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
14. Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report.
Sun K; Nie L; Nong L; Cheng Y
Thorac Cancer; 2021 Jun; 12(12):1927-1930. PubMed ID: 33960639
[TBL] [Abstract][Full Text] [Related]
15. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
Zhou C; Kim SW; Reungwetwattana T; Zhou J; Zhang Y; He J; Yang JJ; Cheng Y; Lee SH; Bu L; Xu T; Yang L; Wang C; Liu T; Morcos PN; Lu Y; Zhang L
Lancet Respir Med; 2019 May; 7(5):437-446. PubMed ID: 30981696
[TBL] [Abstract][Full Text] [Related]
16. VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
Hu S; Li Q; Peng W; Feng C; Zhang S; Li C
J Thorac Oncol; 2018 May; 13(5):e72-e74. PubMed ID: 29703539
[No Abstract] [Full Text] [Related]
17. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
Paik J; Dhillon S
Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
[TBL] [Abstract][Full Text] [Related]
18. Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients.
Groenland SL; Geel DR; Janssen JM; de Vries N; Rosing H; Beijnen JH; Burgers JA; Smit EF; Huitema ADR; Steeghs N
Clin Pharmacol Ther; 2021 Feb; 109(2):394-402. PubMed ID: 32686074
[TBL] [Abstract][Full Text] [Related]
19. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Nishio M; Nakagawa K; Mitsudomi T; Yamamoto N; Tanaka T; Kuriki H; Zeaiter A; Tamura T
Lung Cancer; 2018 Jul; 121():37-40. PubMed ID: 29858024
[TBL] [Abstract][Full Text] [Related]
20. A selective ALK inhibitor in ALK-rearranged patients.
Yang JC
Lancet Oncol; 2013 Jun; 14(7):564-5. PubMed ID: 23639469
[No Abstract] [Full Text] [Related]
[Next] [New Search]